Cannabis Stocks And ETFs Surge As DEA Moves To Reschedule Marijuana

The cannabis sector saw a notable upswing on Tuesday on news of the Drug Enforcement Administration’s (DEA) historic decision to align its stance with a recommendation from the Department of Health and Human Services and move marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

Earlier this year the Dept. of Health and Human Services (HHS) released 252 pages of documents confirming for the first time it recommended to the DEA to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act.

The documents explained that cannabis “has a currently accepted medical use in treatment in the United States” and that it has a “potential for abuse less than the drugs or other substances in Schedules I and II.”

Now, investors seem optimistic about potential regulatory changes that could benefit the cannabis industry.

See also: DEA’s Cannabis Classification: Time To Right A Decades-Old Mistake As Feds Confirm Marijuana’s Medical Benefits

Pro tip: Learn all about the future of the cannabis industry at the …

Full story available on Benzinga.com